Pharmaceutical - Antibiotics and Infectious diseases


Popular Filters

201 to 225 of 229 results

Common antifungal drug thiabendazole shows promise as cancer therapy


An inexpensive US Food and Drug Administration approved antifungal drug, thiabendazole, slows tumor growth…

Antibiotics and Infectious diseasesOncologyPharmaceuticalResearchthiabendazole

AstraZeneca/BTG abandon CytoFab for sepsis as it fails in Ph IIb


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has decided to halt any further development of AZD9773…

Antibiotics and Infectious diseasesAstraZenecaBTGCytoFabLicensingPharmaceuticalResearch

BioAlliance Pharma out-licenses Oravig to Vestiq Pharma for the USA


BioAlliance Pharma out-licenses Oravig to Vestiq Pharma for the USA

Antibiotics and Infectious diseasesBioAlliance PharmaLicensingLoramycNorth AmericaOravigPharmaceuticalVestiq Pharmaceuticals

UK's NICE launches new medicines advisory service


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) last Friday launched…

Antibiotics and Infectious diseasesAstellas PharmaBiotechnologyDificlirEuropeGenericsPharmaceuticalRegulation

Single silk device can store and deliver vaccine or antibiotic without costly cold chain


Researchers at the USA-based Tufts University School of Engineering have discovered a way to maintain…

Antibiotics and Infectious diseasesPharmaceuticalResearchVaccines

Boehringer Ingelheim links with Harvard for unmet medical needs research


Family-controlled German drug major Boehringer Ingelheim has established a translational research collaboration…

Antibiotics and Infectious diseasesBoehringer IngelheimOncologyPharmaceuticalResearch

TaiGen Biotech out-licenses China rights for nemonoxacin, to Zhejiang Medicine


Taiwan-based TaiGen Biotechnology and China's Zhejiang Medicine Company (SHA: 600216) have signed an…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyZhejiang Medicine

Cubist unveils five-year strategic goals; enters antibiotics collaboration


USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations - Building…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsEnteregFinancialFundacion MEDINAPharmaceuticalResearch

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe


USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Positive Ph IIb results for Otsuka TB drug candidate delamanid


Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) has announced Phase IIb clinical trial results on…

Antibiotics and Infectious diseasesdelamanidOtsukaPharmaceuticalResearchRespiratory and Pulmonary

Forest acquires rights to Nabriva antibacterial and option to buy firm


US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

Meiji Seika to expand in Russian pharmaceutical market


Japanese drugmaker Meiji Seika Pharma has signed a partnership agreement with R-Pharm, one of Russia's…

Antibiotics and Infectious diseasesEuropeLicensingMarkets & MarketingMeiji Seika PharmaPharmaceuticalR-Pharma

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Concerns over drug resistance in Gram-negative infections has led to changes in drug usage in USA


Piperacillin-tazobactam is a leading and preferred therapy for Gram-negative infections (GNIs), accounting…

Antibiotics and Infectious diseasesMarkets & MarketingNorth AmericaPharmaceutical

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated


ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Optimer Pharma could earn $90 million from new Astellas deal


US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

New pathway proposed for antibiotic approval in USA


The US Congress will consider a new drug approval pathway to encourage development of critically needed,…

Antibiotics and Infectious diseasesNorth AmericaPharmaceuticalRegulationResearch

Daiichi Sankyo and Terumo link up for vaccine development


Drug major Daiichi Sankyo (TYO: 4568) and fellow Japanese company Terumo Corp (TYO: 4543) have entered…

Antibiotics and Infectious diseasesDaiichi SankyoPharmaceuticalResearchTerumoVaccines

Additional indications in Japan for Diagnogreen and Sawacillin


Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Hospira challenges Cubist patents on Cubicin


US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

GlaxoSmithKline pauses four UTI drug trials


UK pharma giant GlaxoSmithKline (LSE: GSK) has voluntarily paused enrollment in its current clinical…

Anacor PharmaceuticalAntibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalResearch

201 to 225 of 229 results

Back to top